









Markets
/
Stocks
/
nasdaq-aytu
/

Aytu Biopharma Inc

AYTU

2.200USD

+0.070+3.29%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

19.75MMarket Cap

LossP/E TTM



Aytu Biopharma Inc

2.200

+0.070+3.29%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aytu Biopharma Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aytu Biopharma Inc's Score

Industry at a Glance

Industry Ranking

80 / 159

Overall Ranking

229 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.167

Target Price

+314.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aytu Biopharma Inc Highlights

StrengthsRisks

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Growing

The company is in a growing phase, with the latest annual income totaling USD 66.38M.

Fairly Valued

The company’s latest PE is -0.99, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.42M shares, increasing 27.84% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 89.91K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.49.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.81, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.13M, representing a year-over-year decrease of 15.80%, while its net profit experienced a year-over-year decrease of 329.24%.

Score

Industry at a Glance

Previous score

7.81

Change



Financials

6.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Aytu Biopharma Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.38, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.99, which is -1414.10% below the recent high of 12.96 and -116.72% above the recent low of -2.14.

Score

Industry at a Glance

Previous score

7.38

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 80/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Aytu Biopharma Inc is 8.00, with a high of 12.50 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.167

Target Price

+330.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Aytu Biopharma Inc

AYTU

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.40, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 2.45 and the support level at 1.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

-0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Neutral

RSI(14)

46.032

Neutral

STOCH(KDJ)(9,3,3)

26.491

Neutral

ATR(14)

0.128

Low Volatility

CCI(14)

-109.927

Sell

Williams %R

78.149

Sell

TRIX(12,20)

-0.013

Sell

StochRSI(14)

33.313

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.198

Buy

MA10

2.211

Sell

MA20

2.282

Sell

MA50

2.242

Sell

MA100

2.267

Sell

MA200

1.845

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 33.56%, representing a quarter-over-quarter decrease of 7.24%. The largest institutional shareholder is James Simons, holding a total of 89.91K shares, representing 0.88% of shares outstanding, with 27.81% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nantahala Capital Management, LLC

1.09M

Stonepine Capital Management, LLC

812.68K

+75.25%

AWM Investment Company, Inc.

619.87K

Kanen Wealth Management, LLC

573.36K

+244.84%

Lytton (Laurence W)

506.61K

Disbrow (Joshua R.)

153.26K

+76.99%

Renaissance Technologies LLC

Star Investors

89.91K

+17.04%

Disbrow (Jarrett T)

29.46K

+130.24%

Geode Capital Management, L.L.C.

53.87K

-0.14%

Selhorn (Ryan J)

16.00K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.46, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.